Overview

Individualized Drug Treatment for Treating Patients With Pancreatic Cancer

Status:
Terminated
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Treating tumor tissue in the laboratory with different drugs may help doctors find the best drug for treating individual patients with pancreatic cancer. PURPOSE: This phase II trial is studying an individualized drug treatment selection process, based on laboratory results, for treating patients with pancreatic cancer that can be removed by surgery.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborator:
National Cancer Institute (NCI)
Treatments:
Antineoplastic Agents
Bortezomib
Capecitabine
Cetuximab
Docetaxel
Erlotinib Hydrochloride
Gemcitabine
Irinotecan
Mitomycin
Mitomycins
Sirolimus
Thalidomide